Cargando…
An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect
BACKGROUND: Diffuse Midline Glioma, H3K27M-mutant (DMG) is a rare, highly aggressive pediatric tumor affecting the brainstem, and is one of the deadliest cancers. Currently available treatment options such as chemotherapy and radiotherapy do only modestly prolong survival. In this pathology, H3K27 m...
Autores principales: | Rahal, Farah, Capdevielle, Caroline, Rousseau, Benoit, Izotte, Julien, Dupuy, Jean-William, Cappellen, David, Chotard, Guillaume, Ménard, Mélissa, Charpentier, Justine, Jecko, Vincent, Caumont, Charline, Gimbert, Edouard, Grosset, Christophe F, Hagedorn, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923007/ https://www.ncbi.nlm.nih.gov/pubmed/35300150 http://dx.doi.org/10.1093/noajnl/vdac018 |
Ejemplares similares
-
Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas
por: Keane, Lily, et al.
Publicado: (2021) -
Comparative drug screening in NUT midline carcinoma
por: Beesley, A H, et al.
Publicado: (2014) -
Intramedullary Spinal Cord Lesions: A Single-Center Experience
por: Jecko, Vincent, et al.
Publicado: (2022) -
The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
por: Steele, J C, et al.
Publicado: (2006) -
A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis
por: Dhar, Swati, et al.
Publicado: (2022)